Engineered Nanoprobes for Immune Activation Monitoring
Source abstract
Abstract
The activation of the immune system is critical for cancer immunotherapy and treatments of inflammatory diseases. Non-invasive visualization of immunoactivation is designed to monitor the dynamic nature of the immune response and facilitate the assessment of therapeutic outcomes, which, however, remains challenging. Conventional imaging modalities, such as positron emission tomography, computed tomography, etc., were utilized for imaging immune-related biomarkers. To explore the dynamic immune monitoring, probes with signals correlated to biomarkers of immune activation or prognosis are urgently needed. These emerging molecular probes, which turn on the signal only in the presence of the intended biomarker, can improve the detection specificity. These probes with “turn on” signals enable non-invasive, dynamic, and real-time imaging with high sensitivity and efficiency, showing significance for multifunctionality/multimodality imaging. As a result, more and more innovative engineered nanoprobes combined with diverse imaging modalities were developed to assess the activation of the immune system. In this work, we comprehensively review the recent and emerging advances in engineered nanoprobes for monitoring immune activation in cancer or other immune-mediated inflammatory diseases and discuss the potential in predicting the efficacy following treatments. Research on real-time in vivo immunoimaging is still under exploration, and this review can provide guidance and facilitate the development and application of next-generation imaging technologies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, People’s Republic of China
Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, People’s Republic of China
Funding
Chinese Academy of Medical Sciences · National Natural Science Foundation of China
References (100+)
Show source-provided references
1. 10.1021/acsami.1c0878510.1021/acsami.1c08785 ↗
2. 10.3892/ijmm.6.1.310.3892/ijmm.6.1.3 ↗
3. 10.1021/acs.chemrev.1c0071610.1021/acs.chemrev.1c00716 ↗
4. 10.1021/acsnano.1c0858510.1021/acsnano.1c08585 ↗
5. 10.1038/nrd350010.1038/nrd3500 ↗
6. 10.1016/j.apsb.2019.09.00610.1016/j.apsb.2019.09.006 ↗
7. 10.1016/j.apsb.2022.02.02310.1016/j.apsb.2022.02.023 ↗
8. 10.1021/acs.nanolett.1c0064810.1021/acs.nanolett.1c00648 ↗
9. 10.1016/j.apsb.2022.05.03210.1016/j.apsb.2022.05.032 ↗
10. 10.1038/nrc323910.1038/nrc3239 ↗
11. 10.1016/j.apsb.2021.03.00410.1016/j.apsb.2021.03.004 ↗
12. 10.1021/acsnano.9b0906510.1021/acsnano.9b09065 ↗
13. 10.1016/j.coi.2009.03.00210.1016/j.coi.2009.03.002 ↗
14. 10.1016/j.apsb.2020.10.02010.1016/j.apsb.2020.10.020 ↗
15. 10.1016/j.ygyno.2022.03.01310.1016/j.ygyno.2022.03.013 ↗
16. 10.1007/s00262-008-0576-410.1007/s00262-008-0576-4 ↗
17. 10.1002/adma.20200321410.1002/adma.202003214 ↗
18. 10.1038/s41573-020-0082-810.1038/s41573-020-0082-8 ↗
19. 10.1039/C9NH00514E10.1039/C9NH00514E ↗
20. 10.1002/adma.20210900410.1002/adma.202109004 ↗
21. 10.3389/fimmu.2020.0106710.3389/fimmu.2020.01067 ↗
22. 10.1016/j.colsurfb.2018.08.05710.1016/j.colsurfb.2018.08.057 ↗
23. 10.1155/2012/86374710.1155/2012/863747 ↗
24. 10.1002/jcb.2830810.1002/jcb.28308 ↗
25. 10.1021/jacs.0c0065910.1021/jacs.0c00659 ↗
26. 10.1007/s00330-018-5814-310.1007/s00330-018-5814-3 ↗
27. 10.1002/ijc.3232710.1002/ijc.32327 ↗
28. 10.1016/j.immuni.2018.03.01410.1016/j.immuni.2018.03.014 ↗
29. 10.1126/scitranslmed.aad711810.1126/scitranslmed.aad7118 ↗
30. 10.1038/s41577-020-0306-510.1038/s41577-020-0306-5 ↗
31. 10.1038/nri.2017.11210.1038/nri.2017.112 ↗
32. 10.1038/nrc323910.1038/nrc3239 ↗
33. 10.1038/s41377-021-00628-010.1038/s41377-021-00628-0 ↗
34. 10.1038/s41587-019-0262-410.1038/s41587-019-0262-4 ↗
35. 10.1021/acsapm.0c0071110.1021/acsapm.0c00711 ↗
36. 10.1021/acsapm.1c0121610.1021/acsapm.1c01216 ↗
37. 10.1021/acsmacrolett.9b0039910.1021/acsmacrolett.9b00399 ↗
38. 10.1021/acs.biomac.8b0117110.1021/acs.biomac.8b01171 ↗
39. 10.1007/s12274-015-0712-310.1007/s12274-015-0712-3 ↗
40. 10.1021/acsnano.0c0531710.1021/acsnano.0c05317 ↗
41. 10.1038/nm0103-12310.1038/nm0103-123 ↗
42. 10.7150/thno.734110.7150/thno.7341 ↗
43. 10.1016/j.canlet.2017.11.01910.1016/j.canlet.2017.11.019 ↗
44. 10.1016/j.ctrv.2018.09.00710.1016/j.ctrv.2018.09.007 ↗
45. 10.1002/adhm.20170026210.1002/adhm.201700262 ↗
46. 10.1016/j.molmed.2012.09.00910.1016/j.molmed.2012.09.009 ↗
47. 10.1038/cdd.2009.20610.1038/cdd.2009.206 ↗
48. 10.1515/hsz-2013-023810.1515/hsz-2013-0238 ↗
49. 10.1002/cmdc.20210026010.1002/cmdc.202100260 ↗
50. 10.1126/sciadv.abc277710.1126/sciadv.abc2777 ↗
51. 10.1161/CIRCRESAHA.115.30636410.1161/CIRCRESAHA.115.306364 ↗
52. 10.1038/s41551-022-00852-y10.1038/s41551-022-00852-y ↗
53. 10.1159/00032417610.1159/000324176 ↗
54. 10.1002/anie.20201142910.1002/anie.202011429 ↗
55. 10.1002/anie.20201511610.1002/anie.202015116 ↗
56. 10.1016/S0002-9440(10)63580-810.1016/S0002-9440(10)63580-8 ↗
57. 10.1016/j.ccr.2009.06.01710.1016/j.ccr.2009.06.017 ↗
58. 10.1172/JCI7705310.1172/JCI77053 ↗
59. 10.1002/anie.20220318410.1002/anie.202203184 ↗
60. 10.1016/j.chembiol.2022.08.00610.1016/j.chembiol.2022.08.006 ↗
61. 10.1038/s41467-022-29691-w10.1038/s41467-022-29691-w ↗
62. 10.1016/j.jjcc.2010.10.00110.1016/j.jjcc.2010.10.001 ↗
63. 10.1038/nchembio.60710.1038/nchembio.607 ↗
64. 10.1016/j.immuni.2012.10.02010.1016/j.immuni.2012.10.020 ↗
65. 10.1155/2016/158096710.1155/2016/1580967 ↗
66. 10.1002/adma.20190631410.1002/adma.201906314 ↗
67. 10.1038/s41579-020-0367-210.1038/s41579-020-0367-2 ↗
68. 10.1016/j.immuni.2018.10.01310.1016/j.immuni.2018.10.013 ↗
69. 10.1016/j.it.2012.09.00110.1016/j.it.2012.09.001 ↗
70. 10.3389/fimmu.2019.0278710.3389/fimmu.2019.02787 ↗
71. 10.1016/j.freeradbiomed.2018.05.08610.1016/j.freeradbiomed.2018.05.086 ↗
72. 10.1016/j.bioactmat.2020.07.01310.1016/j.bioactmat.2020.07.013 ↗
73. 10.1016/j.biomaterials.2017.08.00810.1016/j.biomaterials.2017.08.008 ↗
74. 10.1021/acs.analchem.0c0536410.1021/acs.analchem.0c05364 ↗
75. 10.1016/j.bioactmat.2021.08.01010.1016/j.bioactmat.2021.08.010 ↗
76. 10.1038/cr.2009.13710.1038/cr.2009.137 ↗
77. 10.1158/0008-5472.CAN-08-244210.1158/0008-5472.CAN-08-2442 ↗
78. 10.1038/nrd222210.1038/nrd2222 ↗
79. 10.1189/jlb.69.4.52210.1189/jlb.69.4.522 ↗
80. 10.1021/jacs.1c1145510.1021/jacs.1c11455 ↗
81. 10.1038/nbt.398710.1038/nbt.3987 ↗
82. 10.1016/j.cmet.2019.06.00110.1016/j.cmet.2019.06.001 ↗
83. 10.3390/ijms2212656010.3390/ijms22126560 ↗
84. 10.3389/fonc.2020.56651110.3389/fonc.2020.566511 ↗
85. 10.3389/fimmu.2014.0061410.3389/fimmu.2014.00614 ↗
86. 10.1016/j.ejphar.2020.17309010.1016/j.ejphar.2020.173090 ↗
87. 10.1038/ncomms569610.1038/ncomms5696 ↗
88. 10.1038/s41467-020-14433-710.1038/s41467-020-14433-7 ↗
89. 10.1002/adma.20200064810.1002/adma.202000648 ↗
90. 10.1016/S0021-9258(17)30079-010.1016/S0021-9258(17)30079-0 ↗
91. 10.1038/s41551-020-0592-z10.1038/s41551-020-0592-z ↗
92. 10.3390/ijms2216873610.3390/ijms22168736 ↗
93. 10.1021/acs.molpharmaceut.9b0001010.1021/acs.molpharmaceut.9b00010 ↗
94. 10.1016/S0076-6879(04)85001-810.1016/S0076-6879(04)85001-8 ↗
95. 10.1093/ilar.42.3.21910.1093/ilar.42.3.219 ↗
96. Strauss L. G. · J. Nucl. Med. · 1991 · 32 · 623
97. 10.7150/thno.3598910.7150/thno.35989 ↗
98. 10.1016/j.trecan.2018.03.00910.1016/j.trecan.2018.03.009 ↗
99. 10.1158/0008-5472.CAN-16-295310.1158/0008-5472.CAN-16-2953 ↗
100. 10.1182/blood.V61.4.660.66010.1182/blood.V61.4.660.660 ↗